Table 10.
Clinical trials on the use of PD-1 inhibitors for recurrent/metastatic EBV-related tumors
| Trial | Phase | Setting | Enrollment | Agent | Combination therapy | Efficacy |
|---|---|---|---|---|---|---|
| Ma399 NCT02339558 | II | R/M NPC | 40 | Nivolumab | NO | Completed |
| NCT02054806 | Ib | R/M NPC | 44 | Pembrolizumab | NO | Completed |
| NCT02875613 | II | R/M NPC | 39 | Avelumab | NO | Ongoing |
| NCT03707509 | III | R/M NPC | 250 | Camrelizumab | Gemcitabine, Cisplatin | Ongoing |
| NCT02605967 | II | R/M NPC | 114 | PDR001 | Gemcitabine,capecitabine ordocetaxel | Ongoing |
| NCT03813394 | I/II | R/M NPC | 48 | pembrolizumab | bevacizumab | Ongoing |
| NCT02611960 | III | R/M NPC | 124 | Pembrolizumab | Gemcitabine, capecitabine | Ongoing |
| NCT03854838 | II | R NPC | 25 | Tolipalimab | IMRT | Ongoing |
| NCT03907826 | III | R NPC | 212 | Toripalimab | IMRT | Ongoing |
| NCT03930498 | II | R NPC | 43 | Toripalimab | Cisplatin and Gemcitabine IMRT | Ongoing |
| NCT03755440 | II | M GC | 20 | SHR-1210 | NO | Ongoing |
| NCT03015896 | I/II | R NHL/HL | 102 | Nivolumab | Lenalidomide | Ongoing |
| NCT02973113 | I | R/R HL | 8 | Nivolumab | EBVST Cells | Ongoing |
| NCT02950220 | I | R/R NHL | – | Pembrolizumab | Ibrutinib | Completed |
| Fang403 NCT03121716 | I | R/M NPC | 20 | SHR-1210 | Gemcitabine Cis-platinum | Completed |
R/M recurrent/metastatic, R recurrent, M metastatic, NPC nasopharyngeal carcinoma, GC gastric cancer, R/R relapsed/refractory, NHL non-Hodgkin lymphoma, HL Hodgkin lymphoma